<DOC>
	<DOCNO>NCT03082833</DOCNO>
	<brief_summary>Phase II trial AZD2014 TSC1/2 mutate TSC1/2 null GC patient second-line chemotherapy</brief_summary>
	<brief_title>Phase II Trial AZD2014 TSC1/2 Mutated TSC1/2 Null GC Patients Second-line Chemotherapy</brief_title>
	<detailed_description>AZD2014 50mg BD continuous schedule 28 day cycle AZD2014 administer orange juice STG/TG patient . AZD2014 take without food . The first dose day take approximately time morning.The second dose day take approximately 12 hour morning dose .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Provision fully inform consent prior study specific procedure . 2 . Patients must ≥20 year age . 3 . Advanced gastric adenocarcinoma ( include GEJ ) progress firstline therapy . The 1st line regimen must contain doublet 5fluoropyrimidine platinum base regimen . Relapse within 6 month completion adjuvant/neoadjuvant chemotherapy contain doublet 5fluoropyrimidine platinumbased regimen could consider 1st line therapy . Acceptable prior chemotherapy regimen protocol chemotherapy regimen include Immune Target agent therapy . ( pembrolizumab , ramucirumab etc ) 4 . Previous adjuvant/neoadjuvant chemotherapy allow , complete 6 month prior start 1st line therapy . 5 . Provision tumor sample ( eith tumor sample ( eith tumor sample ( eith tumor sample ( eith tumor sample ( eith er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) er resection biopsy ) 6 . Patients TSC1/2 mutation null VIKTORY trial . ( The VIKTORY trial use Ion Torrent PGM screen panel cancer mutation nanostring copy number variation panel ( see addendum VIKTORY trial ) . Types TSC1/2 mutation trial define VIKTORY lab manual 7 . Patients willing able comply protocol duration study include undergoing treatment schedule visit examination . 8 . ECOG performance status 02 . 9 . Patients must life expectancy ≥ 3 month propose first dose date . 10 . Patients must acceptable bone marrow , liver renal function measure within 28 day prior administration study treatment define : Haemoglobin ≥9.0 g/dL ( transfusion allow ) Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L White blood cell ( WBC ) &gt; 3 x 109/L Platelet count ≥100 x 109/L ( transfusion allow ) Total bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x institutional upper limit normal unless liver metastasis present case must ≤ 5x ULN Serum creatinine ≤1.5 x institutional ULN 11 . At least one measurable lesion accurately assess image physical examination baseline follow visit . 12 . Negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment day 1 . Patients childbearing potential use adequate contraceptive measure ( two form highly reliable method ) breast feed must negative pregnancy test prior start dosing.Or Patients must evidence nonchildbearing potential fulfil one follow criterion screen : Postmenopausal define age 50 year amenorrhoeic least 12 month follow cessation exogenous hormonal treatment . Documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy , tubal ligation 1 . More one prior chemotherapy regimen ( except adjuvant/neoadjuvant chemotherapy 6 month wash period ) treatment gastric cancer advance set . 2 . Any previous treatment PIK3CA , AKT mTOR inhibitor agent mixed PI3K / mTOR activity . 3 . Patients second primary cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour curatively treat evidence disease ≤5 year . 4 . Patients unable swallow orally administer medication . 5 . Previous major surgery within 4 week prior enrollment . 6 . For AZD2014 : Exposure potent moderate inhibitor inducer CYP3A4/5 take within state washout period first dose study treatment 8 . With exception alopecia , ongoing toxicity ( &gt; CTCAE grade 1 ) cause previous cancer therapy . 9 . Intestinal obstruction CTCAE grade 3 grade 4 upper GI bleeding within 4 week enrollment . 10 . Resting ECG measurable QTcB &gt; 450 msec 2 time point within 24 hour period family history long QT syndrome . 11 . Patients cardiac problem follow : uncontrolled hypertension ( BP ≥150/95 mmHg despite medical therapy ) Left ventricular ejection fraction &lt; 55 % measure echocardiography , Atrial fibrillation ventricular rate &gt; 100 bpm ECG rest , Symptomatic heart failure ( NYHA grade IIIV ) , Prior current cardiomyopathy , Severe valvular heart disease , Uncontrolled angina ( Canadian Cardiovascular Society grade IIIV despite medical therapy ) , Acute coronary syndrome within 6 month prior start treatment 12 . Active untreated brain metastasis spinal cord compression Patients treat brain metastasis spinal cord compression eligible minimal neurologic symptom , evidence stable disease ( least 1 month ) response followup scan , require corticosteroid therapy ≥ 1 week . 13 . Female patient breastfeed childbearing 14 . Any evidence severe uncontrolled systemic disease , active infection , active bleeding diatheses renal transplant , include patient know hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) 15 . Patients proteinuria ( 3+ dipstick analysis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>